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ABSTRACT
Background There has been ongoing controversy as to
whether prosthesisepatient mismatch (PPM, defined as
indexed effective orifice area (EOAI) <0.85 m2/cm2)
influences mortality after aortic valve replacement (AVR).
In most studies, PPM is anticipated by reference tables
based on mean EOAs as opposed to individual
assessment. These reference values may not reflect the
actual in vivo EOAI and hence, the presence or absence
of PPM may be based on false assumptions.
Objective To assess the impact of small prosthesis EOA
on survival after aortic valve replacement AVR.
Methods 645 patients had undergone an AVR between
2000 and 2007 entered the study. All patients underwent
transthoracic echocardiography for determination of the
actual EOAI within 6 months postoperatively. In order to
predict time from surgery to death a proportional hazards
model for competing risks (cardiac death vs death from
other causes) was used. EOAI was entered as
a continuous variable.
Results PPM occurred in 40% of the patients. After
a median follow-up of 2.35 years, 92.1% of the patients
were alive. The final Cox regression model showed
a significantly increased risk for cardiac death among
patients with a smaller EOAI (HR¼0.32, p¼0.022). The
effect of EOAI on the 2e5 year mortality risk was
demonstrated by risk plots.
Conclusions In contrast to previous studies these EOAI
values were obtained through postoperative echocardi-
ography, substantially improving the accuracy of
measurement, and the EOAI was modelled as
a continuous variable. There was a significantly improved
survival for larger EOAIs following AVR. Strategies to
avoid PPM should become paramount during AVR.
The concept of prosthesisepatient mismatch (PPM)
was first introduced by Rahimtoola,1 and occurs
when the effective orifice area of an aortic valve
prosthesis is considered to be too small in relation to
a patient’s body size.2 PPM reflects residual aortic
stenosis and, consequently, may lead to incomplete
left ventricular mass regression and possibly
decreased survival after aortic valve replacement
(AVR).Themajority of studies evaluating the impact
of PPM on outcomes following AVR have relied on
effective orifice area (EOA) estimations obtained
frompreviously published reference tables.However,
individual echocardiographic EOA measurements
might more accurately account for interindividual
variety in the EOAof patients. Furthermore, the EOA
index (EOAI) has predominantly been studied as
a categorical variable, whereas its analysis as
a continuous variable is likely to be a more appro-
priate means of establishing its impact on morbidity
and mortality following AVR. The aim of our study
was to investigate the impact of EOAI on mid-term
survival in patients undergoingAVR, analysing EOAI
as a continuous rather than categorical variable.
METHODS
We analysed our outpatient clinic database and
identified 645 patients who had undergone biopros-
thetic primary AVR between July 2000 and January
2007, with at least 6 months of follow-up. These
patients had undergone echocardiography for post-
operative calculation of theEOAI. Between July 2007
and December 2007, follow-up data were collected
from these patients using a questionnaire, and
patient survival status was assessed by scrutinising
hospital records. Baseline characteristics and opera-
tive data are summarised in table 1 with respect
to an EOAI of $0.85 cm2/m2 or <0.85 cm2/m2. All
patients signed an informed consent form.
Echocardiography
Echocardiography was performed 6.561.5 months
postoperatively. All examinations were performed
by a single dedicated and experienced echocardiog-
rapher. Echocardiography was carried out using an
image Point Hx ultrasound system with a 2.5 MHz
transducer (Hewlett Packard, USA). Peak and mean
systolic pressure gradients in the left ventricular
outflowtract (LVOT)weremeasured 1 cmbelow the
valve in an apical three- or five-chamber view. Pulsed-
wave Doppler was used for LVOT measurements
and continuous-wave Doppler for the transvalvular
measurements. In patients who were in sinus
rhythm the three best available signals were aver-
aged. If atrial fibrillation was present a minimum of
five measurements was averaged.
EOA was obtained using the continuity equa-
tion.3 EOAI is the EOA indexed to body surface
area, where body surface area is derived from the
Dubois formula.4 For descriptive data, PPM was
defined as present in patients with an EOAI
#0.85 cm2/m2.5e9
Left ventricular mass (LVM) was obtained with
the PenneCube formula.10 Data for LVM calcula-
tion were complete in 581 patients. A residual left
ventricular hypertrophy (LVH) was defined as an
indexed LVM of >125 g/m2.11
Statistical analysis
This is a retrospective review of a consecutive
series of patients who underwent AVR with
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a bioprosthesis. Data are expressed as mean values 6 standard
deviation for continuous variables, and as percentages for cate-
gorical variables. We considered time from operation to death as
clinical end point. As cardiac death was the event of interest, we
treated death due to other (non-cardiac) causes as possible
competing risk. Therefore, we used techniques for analysing
survival in a competing risk settingdnamely, cumulative inci-
dence functions for estimating the probability of the interesting
events, Gray ’s test12 for comparing groups, and for multivariate
modelling purposes the proportional hazardsmodel for competing
risks proposed by Fine and Gray.13 For modelling competing risks,
we used complete cases with regard to the cause of death and the
covariates of EOAI, age at time of operation, gender, arterial
hypertension, chronic obstructive pulmonary disease, nicotine
abuse, diabetes mellitus, coronary heart disease, preoperative
ejection fraction, hyperlipidaemia, previous myocardial infarc-
tion, previous cardiac surgery, peripheral vessel disease, carotid
stenosis, liver disease, gastrointestinal disease, malignant tumour,
renal insufficiency, coagulopathy, psychiatric disease, atrial
fibrillation and concomitant procedures. Using the proportional
hazards model for competing risks, we developed a multivariate
prognostic model which contains all the above-mentioned cova-
riates statistically significant in the bivariate models at the 10%
level. Further, the model fit (proportional hazards assumption,
influential observations) of the resulting multivariate propor-
tional hazards model was assessed by adequate diagnostic tools.
Finally, we performed a sensitivity analysis for the subgroup of
patients with a body mass index (BMI) of #30 kg/m2. All calcu-
lations were performed in SPSS (SPSS 16.0) and R (version 2.9.2).
RESULTS
Effective orifice area measurements
The mean EOAs obtained echocardiographically for each valve
size and type are summarised in table 2.
By anticipating the presence or absence of PPM (defined as
EOAI <0.85 cm2/m2) with EOA charts containing the greatest
amount of published data,14 92 patients (14.3%) would have
been correctly identified as presenting a PPM, 347 patients
(53.9%) would have correctly been identified as not presenting
a PPM, and 42 (6.5%) and 163 (25.3%), respectively, would have
had a false-positive and false-negative prediction, respectively.
Figure 1 further demonstrates that the EOA is not a constant
predictable value by showing the EOA measurement distribu-
tion in n¼113 patients who had had implanted the same valve
type and size. The EOA measurements ranged from 0.88 cm2 to
3.49 cm2 with a mean value of 1.82 cm2 and a SD of 0.413 cm2.
Survival analysis with competing risks using categorised EOAI
We collected data of 645 patients of whom 630 patients had
information on all covariates (97.7% of all patients). A total of
51 events occurred during the follow-up period. Eight patients
who died from unknown cause were excluded as they can be
assumed to be missing completely at random. This led to a total
of 622 patients with 43 events. We observed 25 cardiac deaths
and 18 non-cardiac deaths.
As categorisation of the EOAI with a cut-off value of
0.85 cm2/m2 is commonly employed, we present our categorised
data here to allow for improved comparison with other studies.
The incidence of PPM (EOAI<0.85 cm2/m2) in the study
population was 39.9% (248/622).
Mean and median follow-up time was 2.66 years and
2.35 years, respectively, with a range from 0.45 to 7.19 years.
Cumulative incidence of cardiac death 1 year and 5 years after
AVR was 0.8% (95% CI 0.0% to 1.8%) and 5.4% (0.5% to 10.2%)
in patients without PPM versus 2.6% (0.5% to 4.6%) and 10.4%
(3.9% to 16.8%) in patients with PPM (Gray ’s test, p¼0.11, see
figure 2). Cumulative incidence of non-cardiac death 1 and
5 years after AVR was 0.0% (no events observed) and 4.7% (1.3%
to 8.1%) in patients without PPM versus 0.4% (0.0% to 1.3%)
and 5.6% (0.9% to 10.3%) in patients with PPM (Gray ’s test,
p¼0.68).
Subgroup analysis of non-obese (BMI <30 kg/m2) patients
(487 patients with 21 cardiac deaths and 12 non-cardiac deaths)
revealed cumulative incidences for cardiac death of 1.0% (0.0%
to 2.2%) and 6.9% (0.6% to 13.2%) after 1 and 5 years in patients
without PPM versus 2.3% (0.1% to 4.5%) and 12.6% (4.3% to
21.0%) in patients with PPM (Gray ’s test, p¼0.19, see figure 2).
Table 1 Patient characteristics
Characteristics
EOAI‡0.85 cm2/m2
(n[389)
EOAI<0.85 cm2/m2
(n[256) p Value
Age at time of operation
(years), mean6SD
72.367.5 72.367.9 0.946
Body surface area (m2),
mean6SD
1.8560.18 1.8660.19 0.320
Body mass index,
mean6SD
26.663.8 27.464.2 0.011
Gender, female 150 (38.6) 131 (51.2) 0.002
COPD 54 (13.9) 34 (13.3) 0.818
Coronary heart disease 199 (51.3) 141 (55.1) 0.346
Diabetes mellitus 81 (20.9) 78 (30.5) 0.006
Hyperlipidaemia 261 (67.3) 170 (66.4) 0.820
Nicotine abuse 105 (27.1) 59 (23.1) 0.264
Arterial hypertension 314 (80.7) 209 (81.6) 0.770
Previous myocardial
infarction
23 (6.0) 14 (5.5) 0.794
Previous cardiac surgery 22 (5.7) 19 (7.4) 0.382
Peripheral vessel disease 10 (2.6) 12 (4.7) 0.153
Carotid stenosis 26 (6.7) 19 (7.4) 0.739
Liver disease 7 (1.8) 4 (1.6) 0.810
Gastrointestinal disease 18 (4.7) 17 (6.6) 0.280
Malignant tumour 22 (5.7) 24 (9.4) 0.077
Renal insufficiency 26 (6.7) 19 (7.4) 0.739
Coagulopathy 2 (0.5) 2 (0.8) 0.678
Psychiatric disease 0 1 (0.4) 0.219
Atrial fibrillation 50 (13.0) 37 (14.5) 0.587
Residual LVH{ 196/354 (55) 145/227 (64) 0.042
Impaired left ventricular
function
0.798
Ejection fraction
35-50%
70 (18.2) 47 (18.4)
Ejection fraction
<35%
14 (3.6) 12 (4.7)
Concomitant procedure 211 (54.4) 141 (55.3) 0.820
Implanted valve type 0.006
CE Perimount* 156 (40.1) 101 (39.5)
Perimount Magna* 56 (14.4) 56 (21.9)
Medtronic Mosaicy 23 (5.9) 22 (8.6)
Sorin Mitroflowz 33 (8.5) 23 (9.0)
SJM Epic Suprax 30 (7.7) 23 (9.0)
Sorin Soloz 13 (3.3) 7 (2.7)
Sopranoz 43 (11.1) 17 (6.6)
Toronto Rootx 35 (9.0) 7 (2.7)
Results are shown as number (%) unless stated otherwise.
*Edwards Lifesciences (Irvine, California, USA);
yMedtronic (Minneapolis, Minnesota, USA);
zSorin Biomedica (Saluggia, Italy);
xSt Jude Medical (St Paul, Minnesota, USA).
{Residual left ventricular hypertrophy was defined as an indexed left ventricular mass
>125 g/m2.11
COPD, chronic obstructive pulmonary disease; LVH, left ventricular hypertrophy.
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A residual LVH of >125 g/m211 occurred significantly more
often in patients with PPM (145/227, 64%) than in patients
without PPM (196/354, 55%, p¼0.042) at 6 months after AVR.
The cumulative incidence of cardiac death was increased in
patients with residual LVH (2.3% (0.7% to 3.8%) and 10.1%
(3.9% to 16.3%) at 1 and 5 years versus 0.5% (0.0% to 1.5%) and
4.4% (0.0 to 8.9%) in patients with no residual LVH, p¼0.16).
Among patients with residual LVH, those with PPM exhibit
a higher cardiac mortality of 4.1% (0.6% to 7.6%) and 16.4%
(4.0% to 28.8%) at 1 and 5 years, compared with patients with
residual LVH but no PPM (1.3% (0.0% to 2.9%) and 5.9% (0.4%
to 11.3%) and Gray ’s test with p¼0.07, see figure 2).
Multivariate survival analysis with competing risks using EOAI
as a continuous parameter
For the purpose of multivariate modelling, we did not categorise
EOAI to avoid loss of power and other statistical problems.15
The histogram in figure 3 shows the distribution of EOAI in our
patient cohort. As the distribution of EOAI is right skewed we
logarithmically transformed the EOAI to get a more normally
distributed covariate. The bivariate proportional hazards
regression for competing risks (cardiac death as interesting event
and non-cardiac death as competing risk) revealed logarithmic
EOAI (p¼0.068), diabetes mellitus (p¼0.0015), preoperative
ejection fraction (EF) <50% (p¼0.0022) and age at operation
(p¼0.00011) as statistically significant predictors for cardiac
death at the 10% level. These predictors entered simultaneously
the multivariate proportional hazards regression model for
competing risks (table 3). Regression diagnostics did not reveal
any violated assumptions of the proportional hazards regression
model for competing risks. The hazard ratios are given in table 3.
Sensitivity analysis in non-obese patients
Adjusted for the predictors age, diabetes mellitus and preopera-
tive EF <50%, the HR for logarithmic EOAI is 0.31 and statis-
tically significant (p¼0.021) (table 4).
Risk plots
Risk plots for four selected patient profiles were developed to
illustrate the impact of the EOAI on cardiac death (figure 4). The
risk plots indicate the cumulative incidence for cardiac death
after 2, 3, 4 and 5 years in relation to EOAI.
DISCUSSION
Although the concept of ‘prosthesisepatient mismatch’ was
introduced almost 30 years ago, there remains no consensus
about its impact on clinical outcome. Furthermore, there
remains no standardised and universally accepted method for
the calculation of PPM.
After weighing the pros and cons, our group considers echo
measurements the most accurate method to assess the impact of
the EOAI on mortality as opposed to anticipation of EOA. The
key method of our study was to incorporate the EOAI as
a continuous variable. The final multivariate model demon-
strated a significantly increased risk for cardiac death with
smaller EOAI after AVR, while the descriptive analysis using
categorised EOAI did not reach statistical significance. The effect
of EOAI on survival was only significant in the non-obese
patients with a BMI<30 kg/m2, and the cumulative incidence of
cardiac death was strongly increased in patients with residual
LVH and PPM.
Suitability of EOA measurements
In a previous investigation undertaken by our group, we
demonstrated that EOA estimation from reference charts tabu-
lated using data derived from large-scale echocardiography
studies had a sensitivity of 71% and a specificity of 67%,
a positive predictive value of 64%, and a negative predictive
value of 74%14 for the anticipation of PPM. These study data
Table 2 Mean values and ranges of effective orifices areas measured
at 6-month follow-up, according to the models and sizes of prostheses
Prosthesis
Labelled valve size
#19 #21 #23 #25 #27 #29
Edwards Perimount* 1.19
(0.9 to
1.4)
n¼11
1.44
(1.4 to
1.5)
n¼7
1.82
(1.7 to
1.9)
n¼113
1.90
(1.8 to
2.0)
n¼55
2.38
(1.5 to
3.2)
n¼4
2.72
(2.6 to
2.9)
n¼2
Edwards Perimount
Magna*
1.14
(1.0 to
1.3)
n¼10
1.47
(1.4 to
1.6)
n¼47
1.82
(1.7 to
2.0)
n¼38
2.01
(1.8 to
2.2)
n¼17
Medtronic Mosaicz 0.53
n¼1
1.11
(0.9 to
1.3)
n¼9
1.53
(1.3 to
1.8)
n¼23
1.94
(1.6 to
2.2)
n¼10
2.14
(1.6 to
2.7)
n¼2
Sorin Mitroflowx 0.92
n¼1
1.43
(1.3 to
1.6)
n¼20
1.53
(1.4 to
1.7)
n¼19
1.96
(1.8 to
2.1)
n¼12
2.34
(1.7 to
3.0)
n¼4
Sorin Freedom Solox 1.29
n¼1
1.61
(1.2 to
2.1)
n¼3
2.00
(1.6 to
2.3)
n¼7
1.92
(1.3 to
2.6)
n¼5
2.42
(1.9 to
3.0)
n¼4
St Jude Epic Supray 1.46
(1.4 to
1.8)
n¼18
1.81
(1.6 to
2.0)
n¼35
St Jude Toronto Rooty 0.93
n¼1
1.60
(1.4 to
1.8)
n¼6
1.94
(1.7 to
2.2)
n¼16
2.34
(2.1 to
2.6)
n¼11
2.11
(1.7 to
2.5)
n¼8
Labelled valve size
#18 #20 #22 #24 #26 #28
Sorin Sopranox 1.25
(0.9 to
1.7)
n¼3
1.57
(1.4 to
1.7)
n¼15
1.78
(1.7 to
1.9)
n¼20
2.08
(1.8 to
2.3)
n¼18
2.51
(2.1 to
2.6)
n¼3
2.40
n¼1
The numbers in brackets indicate the 95% CI.
*Edwards Lifesciences (Irvine, California, USA);
ySt Jude Medical (St Paul, Minnesota, USA);
zMedtronic (Minneapolis, Minnesota, USA);
xSorin Biomedica (Saluggia, Italy).
Figure 1 Variety of the effective orifice area of one prosthesis type and
size. Histogram of the distribution of the effective orifice area (EOA) in
113 patients who had a prosthesis of the same type and size (Edwards
Perimount size 23) implanted. The mean value of 1.82 cm2 would be the
only character incorporated into a reference table. PPM,
prosthesisepatient mismatch.
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again demonstrate that anticipating the EOA by reference tables
instead of echo measurements would have led to 31.8% false
assignments to PPM/no PPM groups, although this method is
assumed to be better than using geometric or in vitro orifice
area.14 A major reason responsible for the difficulty in accurate
estimation of EOA is the broad interindividual variety of EOA
even when patients are implanted with the same size and type
of prosthesis (figure 1). This phenomenon is attributed to
patient-specific differences in anatomical features of the aortic
root (eg, larger or narrow sinuses of Valsalva) and patient
haemodynamics, which are responsible for the significant
difference in the opening and closing dynamics of individual
prostheses.16 17
Currently, the majority of studies analysing the impact of
PPM on clinical outcome are based on anticipations of PPM. The
determination of EOA using reference tables is a valuable tool,
particularly for intraoperative prediction of whether a patient is
at risk of PPM. Such manoeuvres allowed us to significantly
reduce the incidence of PPM.14 However, the validity of using
reference values, which do not account for individual EOA
variance, to determine the impact of PPM on morbidity or
mortality after AVR, is a subject for discussion. On the other
hand, the Doppler-echocardiographic measurement may be
influenced by several factors that are not necessarily related to
PPM itself, including patient’s flow conditions during the
echocardiographic measurement, subvalvular acceleration, or
measurement errors such as underestimation of LVOT diameter
or misalignment of the Doppler beam with transprosthetic flow
jet. In addition, immediate postoperative measurements are less
likely to be representative as haemodynamics are not well
stabilised at such early time points. Patients investigated early
Figure 2 Cumulative incidence of death after aortic valve replacement.
Top: cumulative incidence of death in the study population (n¼622
patients). Middle: cumulative incidence of death in 487 non-obese
patients (body mass index <30 kg/m2). Bottom: cumulative incidence of
death in 341 patients with residual left ventricular hypertrophy. Solid
black line: cardiac death in patients with prosthesisepatient mismatch
(PPM), effective orifice area index <0.85 cm2/m2); dotted black line:
cardiac death in patients without PPM; solid gray line: non-cardiac death
in patients with PPM; dotted gray line: non-cardiac death in patients
without PPM.
Figure 3 Effective orifice area index (EOAI) distribution. Histogram of
the distribution of the EOAI among the patient population to demonstrate
the continuous nature of the variable. The most commonly used
thresholds for severe (0.65 cm2/m2) and moderate (0.85 cm2/m2) are
drawn into the histogram.
Table 3 Final prognostic model
Predictors for cardiac death HR
Lower limit
95% CI
Upper limit
95% CI p Value
Logarithmic EOAI 0.32 0.12 0.85 0.022
Age 1.11 1.04 1.2 0.003
Diabetes mellitus 2.72 1.19 6.22 0.020
Preoperative ejection fraction <50% 2.3 0.99 5.33 0.052
EOAI, effective orifice area index.
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after AVR are more likely to be in a hyperdynamic state, or
exhibit tachycardia, which makes assessment of the EOA diffi-
cult. Finally, the acoustic window is often of poor quality in the
early postoperative period. To exclude the limitations of early
postoperative measurements, we used the EAO measurements
obtained at a follow-up investigation 6 months after AVR,
which we consider representative and reproducible. We assume
that errors up to 1 cm2 that may occur with the use of the mean
values, as demonstrated in figure 1, are unlikely to result with
the individual echocardiographic assessment of the EOA.
Therefore, our group considered the echo measurements the
most accurate method to assess the impact of the EOAI on mid-
term cardiac-related mortality.
To our knowledge, our study is the largest evaluation of PPM
on survival using individual EOAI measurements. Two previous
studies identifying PPM as an independent predictor for long-
term mortality obtained echocardiographic data at a median
follow-up of 6 days,18 or before discharge.19 According to the
arguments stated above, we question the usefulness of such
early postoperative echocardiographic measurements for char-
acterisation of prosthesis function.
Application of categorised EOAI for survival analysis
Using the EOAI as a categorised variable, our data demonstrate
a remarkably increased cumulative incidence of cardiac death in
patients with PPM (EOAI#0.85 cm2/m2) (figure 2). The inci-
dence of non-cardiac death was similar with or without PPM.
The findings were not statistically significant at the 5% level,
either in the whole cohort or in the subgroups of non-obese
patients and patients with a residual LVH. The EOAI is
conventionally converted into categories by assigning patients
into two groups (‘no PPM’, ‘PPM’),20e25 three groups (‘mild’,
‘moderate’, ‘severe PPM’),5e9 18 or more groups.19 This is partly
driven by predetermination of cut-off values that will provide
a significant association between PPM and outcome. This
practice may contribute to undesirable statistical consequences
like loss of efficiency, biased effect sizes and artificially low p
values.26 Current thresholds for severe and moderate PPM are in
the range 0.6e0.65 cm2/m2 and 0.75e0.90 cm2/m2, further
complicating the comparability of studies. To allow for better
comparison of different studies, it will be essential to standardise
the cut-off values. This study used the most common threshold
of 0.85 cm2/m2.
Application of the continuous EOAI for survival analysis
The key method of this study was to incorporate the EOAI as
a continuous variable. The final multivariate model demon-
strated a significantly increased risk for cardiac death with
smaller EOAI with a hazard ratio of 0.32 in 622 patients who had
Figure 4 Influence of effective orifice
area index (EOAI) on mortality risk. The
risk plots indicate the cumulative
incidence for cardiac death after 2, 3, 4
and 5 years in relation to EOAI. As
indicated by the hazard ratio of 0.32 for
EOAI, the risk of cardiac death after 2, 3,
4 or 5 years decreases with increasing
EOAI for all demonstrated patient
profiles while the slope of the curves
increases with time. Upper left: effect of
EOAI on overall survival after 2, 3, 4 and
5 years after operation for a 72-year-old
patient with no diabetes and an ejection
fraction (EF) >50%. Upper right: impact
of EOAI on overall survival for an
identical patient but with diabetes. As
the hazard ratio of 2.72 for diabetes
increases the risk of death, there is
a higher mortality risk in relation to EOAI
than for the patient with no diabetes.
Bottom left: Additional low EF further
increases the mortality risks after 2,3,4
and 5 years compared with the previous
patient profiles (hazard ratio (HR)¼2.3).
Bottom right: this patient profile shows
the risk for an 82-year-old patient with
impaired EF and diabetes. As age
increases the risk of death (HR¼1.11),
this patient shows the highest risks of
death after 2,3,4 and 5 years compared
with the other three patient profiles,
exhibiting a steeper decrease of
mortality risk with increasing EOAI than
for the other patient profiles.
Table 4 Final prognostic model for non-obese patients
Predictors for cardiac death HR
Lower limit
95% CI
Upper limit
95% CI p Value
Logarithmic EOAI 0.31 0.11 0.84 0.021
Age 1.11 1.03 1.19 0.007
Diabetes mellitus 3.71 1.45 6.95 0.010
Preoperative ejection fraction <50% 1.63 0.65 4.11 0.300
EOAI, effective orifice area index.
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undergone AVR (table 3), while the descriptive analysis using
categorised EOAI did not reach statistical significance. Earlier
studies by Blackstone did model the indexed orifice area as
a continuous variable,27e29 but used the geometric valve area to
determine the presence of PPM.This variablewas later proved tobe
unrelated to postoperative gradients and clinical outcomes.2 Risk
plots for defined patient profiles additionally demonstrated a time-
dependent effect, as the slope of the curves for mortality risk
increased between 2 and 5 years (figure 4). This finding shows that
the negative impact of a smaller EOAI on outcome becomes
increasingly apparentover time, possibly owing to the failure of left
ventricular remodelling over time due to a residual degree of aortic
stenosis. Long-term investigations have demonstrated a significant
divergence of survival curves after 5 years, suggesting that the
effect of PPM might become increasingly influential beyond the
5-year follow-up that was provided in this study.9 18 30 31 As
survival after AVR is certainly affected by multiple factors, we
found, furthermore, a significant influence of patient age, diabetes
and impaired left ventricular function. The impact of these vari-
ables is well recognised in the published literature.5 9 20 21 23 29
Finally, as survival after surgical AVR is usually excellent, and
the number of events is low, adequate proof of an additional effect
of PPM or the EOAI on survival largely depends on most
accurate methodology, which includes respecting the continuous
nature of the EOAI.
Obesity and left ventricular mass
In concordance with a previous study by Mohty et al30 the effect
of EOAI on survival was only significant in the non-obese
patients with a BMI <30 kg/m2. In patients with a BMI
$30 kg/m2, the EOA indexed to the body surface area seems to
be an inadequate tool for estimating PPM.
An impaired LVM regression generated by higher gradients is
assumed to be the main deleterious effect of PPM.22 Our data
showed an increased proportion of patients with a residual LVH
of >125 g/m2 when the EOAI was <0.85 cm2/m2. Furthermore,
the cumulative incidence of cardiac death was strongly increased
in patients with residual LVH and PPM (figure 2, NS). LVM
regression depends on multiple factors, such as initial LVM,32
but PPM remains a factor that can be avoided by the surgeon.
CONCLUSIONS
In summary, our aim was to use improved methodology to
evaluate the impact of PPM on survival after AVR. This was
undertaken using echocardiographically determined EOA
measurements and avoiding analysis of EOAI as a categorical
variable. Our data demonstrate a clinically relevant, significant
impact of smaller EOAIs on cardiac mortality after AVR,
particularly in non-obese patients. Survival is certainly influ-
enced by multiple factors, but PPM remains a factor that can be
avoided by the surgeon. Therefore, we conclude that our data
add important evidence that preventive strategies to avoid PPM
during AVR are reasonable. Such strategies may include intra-
operative anticipation of the EOA by reference tables, implan-
tation of third-generation prostheses with larger EOAs or
annular enlargement in selected patients. Taking into account
our previous findings of impaired exercise capacity in patients
with PPM,33 annular enlargement, in particular, may be advan-
tageous for younger patients in whom PPM is predicted.
Further examinations of the effect of PPM on long-term
mortality or morbidity should preferably use echocardiographic
EOA measurements rather than estimations from reference
tables. This would be helpful in avoiding inaccurate determi-
nations of the presence or absence of PPM. Avoidance of
dichotomisation or categorisation of the EOAI into groups is
likely to further improve the statistical accuracy of follow-up
studies. However, if categorisation is performed, authors should
strive to use the same thresholds, for example, 0.65 cm2/m2 and
0.85 cm2/m2 as proposed by Pibarot and Dumesnil2 and which
are also in concordance with the guidelines for the grading of
native aortic valve stenosis.34
Limitations
Only patients who had 6 months’ follow-up echocardiography
at our institution were included in the study. Therefore, opera-
tive and short-term mortality was not investigated. This might
have created a survival bias as several patients with severe PPM
may have died before 6 months. LVM regression could not be
included in this study, as there were no preoperative measure-
ments. The data of LVM were complete in only 90% of the
patients. As the number of events (25 cardiac deaths) was small,
it will be necessary to increase the length of the follow-up of our
patient group. The EOA was indexed to patients’ body surface
area, thus there might be a rationale for using other variables
such as fat-free body mass.
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